Yahoo MoviesRudy Gay with a 2-pointer vs the Golden State Warriors
Rudy Gay (San Antonio Spurs) with a 2-pointer vs the Golden State Warriors, 01/20/2021
Rudy Gay (San Antonio Spurs) with a 2-pointer vs the Golden State Warriors, 01/20/2021
STORE Capital (NYSE: STOR) invests in single-tenant properties occupied by tenants in the service, retail, and manufacturing industries. You might be surprised to learn that STORE's addressable market of existing properties is several trillion dollars in size. In this Fool Live video clip, recorded on Feb. 16, Millionacres real estate analyst Matt Frankel, CFP, and editor Deidre Woollard discuss how STORE Capital has been doing recently and the enormous addressable market opportunity the company has.
YEREVAN, Armenia — Armenia's prime minister accused top military officers on Thursday of attempting a coup after they demanded he step down, adding fuel to monthslong protests calling for his resignation following the nation's defeat in a conflict with Azerbaijan over the Nagorno-Karabakh region. The demonstrations began immediately after Prime Minister Nikol Pashinyan signed a Nov. 10 peace deal that saw Azerbaijan reclaim control over large parts of Nagorno-Karabakh and surrounding areas that had been held by Armenian forces for more than a quarter-century. Those protests have gathered pace this week, and the feud with his top military commanders has weakened Pashinyan's position. The immediate trigger for the standoff was Pashinyan’s decision to oust the first deputy chief of the military's General Staff, a group of the armed forces' top commanders. In response, the General Staff called for Pashinyan's resignation — but the prime minister doubled down and dismissed the chief of the General Staff. He described the military's statement as a “military coup attempt” and urged troops to only listen to his orders. He also called on his backers to come to the streets and then later walked among them, using a loudspeaker to rally support. “We need a conversation, not a confrontation,” he said. Pashinyan denied rumours that he was preparing to flee the country. Supporters of Pashinyan and the opposition engaged in sporadic scuffles on the streets of Yerevan on Thursday. Russia's government voiced concern over the tensions but emphasized that Armenia needs to sort it out itself. “We are calling for calm and believe that the situation should remain in the constitutional filed,” Kremlin spokesman Dmitry Peskov told reporters. The crisis has its roots in Armenia's humiliating defeat in heavy fighting with Azerbaijan over Nagorno-Karabakh that erupted in late September and lasted 44 days. A Russian-brokered agreement ended the conflict in which the Azerbaijani army routed Armenian forces — but only after more than 6,000 people died on both sides. Pashinyan has defended the peace deal as a painful but necessary move to prevent Azerbaijan from overrunning the entire Nagorno-Karabakh region, which lies within Azerbaijan but was under the control of ethnic Armenian forces backed by Armenia since a separatist war there ended in 1994. Opposition groups have dismissed that argument. On Thursday, opposition demonstrators swarmed the streets of the Armenian capital, chanting “Nikol, you traitor!” and “Nikol, resign!” They paralyzed traffic all around Yerevan. Despite the simmering public anger over the military defeat, Pashinyan has manoeuvred to shore up his rule and the protests died down amid the winter's cold. But the opposition demonstrations resumed with new vigour this week — and then came the spat with top officers. Pashinyan fired the deputy chief of the General Staff, Lt. Gen. Tiran Khachatryan, earlier this week after he derided the prime minister's claim that just 10% of Russia-supplied Iskander missiles that Armenia used in the conflict exploded on impact. The General Staff responded Thursday with a statement demanding Pashinyan's resignation and warned the government against trying to use force against the opposition demonstrators. Immediately after the statement, Pashinyan dismissed the General Staff chief, Col. Gen. Onik Gasparyan. ____ Associated Press writers Vladimir Isachenkov and Daria Litvinova in Moscow contributed to this report. Avet Demourian, The Associated Press
An expected dash by big corporations for offsets to meet their climate targets has prompted financial exchanges to launch carbon futures contracts to capitalise on what could be a multi-billion dollar market. Carbon offsets, generated by emissions reduction projects, such as tree planting or shifts to less polluting fuels, have struggled for years to gain credibility, but as climate action has become urgent, their market is expected to grow to as much as $50 billion by 2030. Among the major corporations that say they expect to use them to compensate for any emissions they cannot cut from their operations and products are Unilever, EasyJet, Royal Dutch Shell and BP, which all have climate targets.
- Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled -- Allogene- and Janssen-Sponsored Phase 1 Trials Evaluating Nirogacestat in Combination with BCMA Therapies Have Initiated - - Continued to Strengthen Nirogacestat Patent Portfolio - - Multiple Data Readouts Expected in 2021 Across Pipeline, Including Topline Data from Phase 3 DeFi Trial in Desmoid Tumors and Initial Nirogacestat BCMA Combination Data - - Ended 2020 with $561.8 Million in Cash, Cash Equivalents and Marketable Securities - STAMFORD, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported fourth quarter and full-year financial results for the period ended December 31, 2020 and provided an update on recent company developments. “2020 was a year characterized by strong performance for SpringWorks as we advanced our diversified targeted oncology portfolio, which currently spans 10 development programs across our three core focus areas: late-stage rare oncology, BCMA combinations in multiple myeloma and biomarker-defined metastatic solid tumors,” said Saqib Islam, Chief Executive Officer of SpringWorks. “Our clinical execution has set the stage for multiple important data readouts in 2021, including the interim ReNeu data announced this morning and topline data from our Phase 3 DeFi trial later this year, and our business development efforts have allowed us to pursue additional combination therapy programs, continuing to grow our portfolio of opportunities across a broad range of potentially high-value and high-unmet need oncology patient settings. We look forward to reporting on our progress throughout 2021.” Recent Business Highlights and Upcoming Milestones Late-Stage Rare Oncology In February 2021, SpringWorks reported interim data from the adult stratum of the ongoing potentially registrational Phase 2b ReNeu trial evaluating mirdametinib in pediatric and adult patients with NF1-associated plexiform neurofibromas. Of the first 20 adult patients enrolled, 50% had achieved an objective response, the primary endpoint of the study, as assessed by blinded independent central review, and 16 of these 20 patients (80%) remained on study as of the January 22, 2021 data cutoff. In addition, mirdametinib was generally well tolerated, with the majority of treatment-related adverse events (TRAE) being Grade 1 or 2 and only one Grade 3 TRAE reported; there have been no Grade 4 or 5 AEs reported. SpringWorks reported that the ReNeu trial has reached approximately 70% of its final enrollment target of 100 patients and the Company expects to complete enrollment of the ReNeu trial in the second half of 2021.SpringWorks expects to report topline data from the Phase 3 DeFi trial in the second half of 2021.Recruitment is ongoing in a Phase 2 study sponsored by the Children’s Oncology Group evaluating nirogacestat in pediatric patients with desmoid tumors. B-cell Maturation Antigen (BCMA) Combinations in Multiple Myeloma Enrollment is ongoing in a Phase 1b trial sponsored by GSK evaluating nirogacestat in combination with BLENREP (belantamab mafodotin-blmf), GSK’s anti-B-cell maturation antigen (BCMA) antibody-drug conjugate, in adult patients with relapsed or refractory multiple myeloma. Initial clinical data from this study are expected in 2021.Two collaborator-sponsored Phase 1 studies were initiated evaluating nirogacestat in combination with BCMA therapies: nirogacestat + Allogene’s ALLO-715 and nirogacestat + Janssen’s teclistamab. SpringWorks also expects that two additional collaborator-sponsored trials will initiate in the first half of 2021, as previously disclosed: nirogacestat + Pfizer’s elranatamab (PF‐06863135) and nirogacestat + Precision’s PBCAR269A. Biomarker-Defined Metastatic Solid Tumors Enrollment is ongoing in a Phase 1b/2 trial evaluating mirdametinib with BeiGene’s RAF dimer inhibitor, lifirafenib, in adult patients with RAS/RAF mutant and other MAPK pathway aberrant solid tumors. BeiGene is sponsoring this trial and SpringWorks and BeiGene expect to report initial clinical data in 2021.Enrollment is ongoing in a Phase 1 trial of BGB-3245 in adult patients with RAF mutant solid tumors. BGB-3245 is a selective RAF dimer inhibitor being developed by MapKure, LLC, a joint venture between SpringWorks and BeiGene. Initial clinical data from the MapKure-sponsored Phase 1 trial are expected in 2021.In December 2020, SpringWorks entered into a research collaboration agreement with Dr. Tatu Pantsar and Dr. Antti Poso at the University of Eastern Finland to conduct novel computational biology research to characterize the effector protein dynamics of different RAS mutations. The objective of the collaboration is to understand the biological consequences of KRAS-effector protein interactions and downstream oncogenic signaling with the goal of guiding patient selection strategies and exploring novel targets for future targeted therapy development. General Corporate In February 2021, a Notice of Allowance was received from the United States Patent and Trademark Office for Patent Application No. 16/886,622 (the ‘622 application) with composition of matter claims covering several polymorphic forms of nirogacestat, including the polymorphic form that is currently in clinical development, which is also covered by U.S. Patent 10,590,087 (the ‘087 patent, issued in March 2020). Pursuant to an existing worldwide license agreement with Pfizer, SpringWorks has exclusive rights to the patent issuing from the ‘622 application. The patent granting from the ‘622 application, as well as the ‘087 patent, will both expire in August 2039.In October 2020, SpringWorks completed a follow-on public offering that raised $269.5 million in net proceeds, which included the underwriters’ full exercise of their option to purchase additional shares of common stock.In October 2020, SpringWorks and Jazz Pharmaceuticals entered into an asset purchase and exclusive license agreement under which Jazz acquired SpringWorks’ fatty acid amide hydrolase (FAAH) inhibitor program. Under the terms of the agreement, Jazz made an upfront payment of $35 million to SpringWorks, with potential future milestone payments of up to $375 million payable to SpringWorks based upon the achievement of certain clinical development, regulatory and commercial milestones. In addition, SpringWorks will receive incremental tiered royalties on future net sales of JZP-150 (formerly PF-04457845) in the mid- to high-single digit percentages. Fourth Quarter and Full Year 2020 Financial Results Revenue: Revenue of $35.0 million for the fourth quarter and year ended December 31, 2020 was attributable to the nonrefundable upfront payment from Jazz in October 2020, related to the asset purchase and exclusive license agreement between SpringWorks and Jazz.Research and Development (R&D) Expenses: R&D expenses were $15.3 million and $51.9 million for the fourth quarter and year-to-date periods, respectively, compared to $12.2 million and $42.5 million for the comparable periods of 2019. The increases in R&D expenses in 2020 were primarily attributable to growth in employee costs associated with increases in the number of R&D personnel, including non-cash share-based compensation expenses, and increases in external costs related to drug manufacturing and clinical trial costs.General and Administrative (G&A) Expenses: G&A expenses were $8.5 million and $29.5 million for the fourth quarter and year-to-date periods, respectively, compared to $5.2 million and $16.7 million for the comparable periods of 2019. The increases in G&A expenses in 2020 were primarily attributable to growth in employee costs associated with increases in the number of G&A personnel supporting the growth of the organization, including non-cash share-based compensation expenses, as well as increases in expenses related to the expansion of business activities.Net Loss Attributable to Common Stockholders: SpringWorks reported net income of $11.3 million, or $0.24 per share, for the fourth quarter, and a net loss of $45.6 million, or $1.05 loss per share, for the year ended December 31, 2020. This compares to net losses of $16.2 million, or $0.39 loss per share, and $50.6 million, or $3.81 loss per share, for the comparable periods of 2019, respectively.Cash Position: Cash, cash equivalents and marketable securities were $561.8 million as of December 31, 2020. This includes the net proceeds of $269.5 million from the Company’s follow-on public offering completed in October 2020, and the $35.0 million upfront payment from Jazz Pharmaceuticals in October 2020, related to the asset purchase and exclusive license agreement between SpringWorks and Jazz. COVID-19 Update To date, the COVID-19 pandemic has had a relatively modest impact on SpringWorks’ business operations, in particular on SpringWorks’ clinical trial programs, and SpringWorks is undertaking considerable efforts to mitigate the various challenges presented by this crisis. For further details and descriptions of the risks associated with the COVID-19 pandemic, please see the Risk Factors in SpringWorks’ periodic filings with the Securities and Exchange Commission and refer to the Forward-Looking Statements section in this press release. About SpringWorks Therapeutics SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn. SpringWorks uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company’s website in the ‘Investors & Media’ section. Accordingly, investors should monitor such portions of the SpringWorks website, in addition to following press releases, SEC filings and public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding SpringWorks’ clinical trials and its strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to SpringWorks’ financial results, the timing for completion of SpringWorks’ clinical trials or third-party clinical trials of its product candidates, the fact that interim results from a clinical study may not be predictive of the final results of such study or the results of other ongoing or future studies, whether and when, if at all, SpringWorks’ product candidates will receive approval from the U.S. Food and Drug Administration, or FDA, or other foreign regulatory authorities, uncertainties and assumptions regarding the impact of the COVID-19 pandemic on SpringWorks’ business, operations, clinical trials involving its product candidates, supply chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in SpringWorks’ SEC filings. SpringWorks cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. SpringWorks disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent SpringWorks’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. SpringWorks Therapeutics, Inc.Consolidated Statements of Operations(Unaudited) Year Ended December 31, (in thousands, except share, unit, per-unit and per-share data) 2020 2019 2018 Licensing revenue $35,000 $— $— Operating expenses: Research and development 51,859 42,545 9,898 General and administrative 29,465 16,694 8,593 Total operating expenses 81,324 59,239 18,491 Loss from operations (46,324) (59,239) (18,491)Other income: Other income 25 — — Interest income, net 1,330 3,547 678 Total other income 1,355 3,547 678 Equity investment loss (605) (2,614) — Net loss $(45,574) $(58,306) $(17,813)Reconciliation of net loss to net loss attributable to common stockholders and unit holders: Net loss $(45,574) $(58,306) $(17,813)Net gain attributable to extinguishment of Series A convertible preferred and Junior Series A convertible preferred units — 7,729 — Net loss attributable to common stockholders and unit holders, basic and diluted $(45,574) $(50,577) $(17,813)Net loss per unit, basic and diluted $— $— $(52.24)Net loss per share, basic and diluted $(1.05) $(3.81) $— Weighted average common units outstanding, basic and diluted — — 341,014 Weighted average common shares outstanding, basic and diluted 43,300,063 13,274,836 — SpringWorks Therapeutics, Inc.Selected Balance Sheet Data(Unaudited) As of December 31,(in thousands) 2020 2019 Cash, cash equivalents and marketable securities $561,820 $ 327,652 Working Capital (1) 495,788 319,391 Total Assets 576,191 334,831 Total liabilities 19,133 12,759 Accumulated deficit (118,603) (73,029)Total stockholders’ (deficit) equity 557,058 322,072 (1) We define working capital as current assets less current liabilities. Contact:Kim DiamondVice President, Communications and Investor RelationsPhone: 203-561-1646Email: kdiamond@springworkstx.com
Granite Construction Incorporated (NYSE: GVA) today reported a net loss of ($153.1) million and ($3.36) per diluted share for the nine months ended September 30, 2020, compared to a net loss of ($40.8) million and ($0.87) per diluted share year-over-year. The net loss for the nine months ended September 30, 2020 included $194.4 million of transaction costs(2), amortization of debt discount, non-recurring legal and accounting investigation costs, and non-cash impairment charges, after-taxes, compared to $26.1 million year-over-year. Excluding the impact of these expenses and charges, adjusted net income(1) for the nine months ended September 30, 2020 was $41.3 million and $0.89 per diluted share compared to an adjusted net loss of ($14.7) million and ($0.31) per diluted share year-over-year. Prior period financial information included herein reflects the impact of the previously disclosed restatement of the first three quarters in the year ended December 31, 2019.
Virgin Galactic Holdings, Inc. (NYSE: SPCE) ("Virgin Galactic"), a vertically integrated aerospace and space travel company, today announced the appointment of Doug Ahrens as its new Chief Financial Officer, effective March 1, 2021. Ahrens will succeed Jon Campagna, who is stepping down as Chief Financial Officer following Virgin Galactic’s successful transition from private to public company.
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccineDiscussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or other new strains that may emerge as possible immune escape virus variants Based on in-vitro studies conducted to date and observations from real world evidence, the Companies have not observed changes to neutralizing antibody levels that would predict a significant reduction in protection provided by two doses of BNT162b2 New York and Mainz, Germany, February 25, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. The study is part of the Companies’ clinical development strategy to determine the effectiveness of a third dose against evolving variants. Separately, in order to be prepared for any potential future strain changes, Pfizer and BioNTech are in ongoing discussions with regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, regarding a registration-enabling clinical study to evaluate a variant-specific vaccine having a modified mRNA sequence. This study would use a new construct of the Pfizer-BioNTech vaccine based on the B.1.351 lineage, first identified in South Africa. This could position the Companies to update the current vaccine quickly if the need arises to protect against COVID-19 from circulating strains. In alignment with the updated guidance issued by the FDA regarding emergency use of vaccines to prevent COVID-19 which provides recommendations for evaluating a modified vaccine to address variants, the Companies are hoping to pursue the validation of future modified mRNA vaccines with a regulatory pathway similar to what is currently in place for flu vaccines. “While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine, we are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine. This booster study is critical to understanding the safety of a third dose and immunity against circulating strains,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “At the same time, we are making the right investments and engaging in the appropriate conversations with regulators to help position us to potentially develop and seek authorization for an updated mRNA vaccine or booster if needed.” “Our proactive clinical development strategy aims to create the foundation today, that will enable us to address the challenges of tomorrow. We want to be prepared for different scenarios,” said Ugur Sahin, CEO and Co-founder of BioNTech. “Therefore, we will be evaluating a second booster in the current regimen as well as preparing for a potential rapid adaption of the vaccine to address new variants which might escape the current version of our mRNA-based vaccine. The flexibility of our proprietary mRNA vaccine platform allows us to technically develop booster vaccines within weeks, if needed. This regulatory pathway is already established for other infectious diseases like influenza. We take these steps in order to ensure a long-term immunity against the virus and its variants.” Administering a third dose will provide an early assessment of the safety of a third dose of BNT162b2, as well as its immunogenicity. The study will evaluate up to 144 Phase 1 participants in two age cohorts, 18-55 and 65-85 years of age. This study will include trial participants who received the two doses in the Phase 1 study 6 to 12 months ago in order to assess the boostability of BNT162b2. Thus, the study will evaluate the safety and tolerability of a third vaccination irrespective of the level of antibody titers of the trial participant. Participants will be assessed at the time they receive the third dose, then one week and one month after, and Pfizer and BioNTech plan to study the ability of the sera from those participants to neutralize SARS-CoV-2 strains of interest. The participants will continue being followed in the study for up to 2 years as originally planned. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine.com. The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorizations Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries. AUTHORIZED USE IN THE U.S.:The Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION: Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 VaccineAppropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 VaccineMonitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/)Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 VaccineThe Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipientsIn clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%)Severe allergic reactions, including anaphylaxis, have been reported following the Pfizer-BioNTech COVID-19 Vaccine during mass vaccination outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 VaccineAvailable data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancyData are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretionThere are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination seriesVaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine EUA” in the description section of the reportVaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com About Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer Disclosure NoticeThe information contained in this release is as of February 25, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program, the mRNA platform and regulatory pathway and the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) (including qualitative assessments of available data, potential benefits, a potential booster dose and a potential new variant-specific vaccine, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the in vitro and Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations upon commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when a Biologics License Application for BNT162b2 may be filed in the U.S. and whether and when other biologics license and/or emergency use authorization applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including a potential Biologics License Application in the U.S.) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. About BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de. BioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential second booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. Pfizer Contacts: Media RelationsJerica Pitts+1 (347) 224-9084Jerica.Pitts@pfizer.com Investor RelationsChuck Triano+1 (212) 733-3901Charles.E.Triano@Pfizer.com BioNTech Contacts: Media RelationsJasmina Alatovic+49 (0)6131 9084 1513Media@biontech.de Investor RelationsSylke Maas, Ph.D.+49 (0)6131 9084 1074Investors@biontech.de
WAYNE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 15, 2021 to shareholders of record at the close of business on March 5, 2021. Additional information about Teleflex can be obtained from the company’s website at www.teleflex.com. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose. Source: Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836
These companies are delivering strong results of late, and there's reason to be optimistic about what's coming next.
In 2000, Intuitive Surgical (NASDAQ: ISRG) went public at $9 per share and launched its da Vinci surgical system. The company's focus on improving medical outcomes and reducing hospitalization and recovery times has benefited patients around the world -- and worked wonders for shareholders. An investor who was able to pick up $1,000 worth of Intuitive Surgical shares at its IPO price and held on has seen that investment grow to a whopping $122,500.
WEX, a leading fintech service provider, further solidified its leadership position in 2020 in terms of growth and services across its Health division
Nomad Foods Limited (NYSE: NOMD), today reported financial results for the three and twelve-month periods ended December 31, 2020.
British television presenter and writer David Walliams and “Doc Martin” star Martin Clunes were among several actors who formally settled damages Thursday with a newspaper publisher over phone hacking claims. Walliams, a judge on “Britain’s Got Talent,” and several others including Clunes sued Mirror Group Newspapers, publisher of tabloids including the Mirror, for illegally intercepting their voicemails. Lawyers for Walliams alleged he and his friends were targeted by the publisher from 2003 to 2010, and that 45 news articles were published as a result of intercepted voicemails and other unlawful techniques.
Virgin Galactic Holdings, Inc. (NYSE: SPCE), a vertically integrated aerospace and space travel company, today announced the appointments of Swami Iyer as its President of Aerospace Systems and Stephen Justice as its Vice President of Engineering.
Before the Sushant Singh Rajput controversy, Rhea had shared her first look from the film.
Munger says the argument for diversification should be called 'diworsification.'
Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Magnetron Sputtering System Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 To 2028" report has been added to ResearchAndMarkets.com's offering. The global magnetron sputtering systems market was valued at US$ 2.23 Bn in 2019 and expected to reach over US$ 3.23 Bn in 2028, growing at a CAGR of 6.5% during the forecast period.Growing scope and applications of magnetron sputtering thin film deposition are driving the demand for magnetron sputtering systems market across the globe. Magnetron sputtering is a thin film deposition technology that allows the deposition of metal, alloys ceramic, and polymer on a number of substrate material. With the technological advancement in the coating processes, this process is widely used in various applications namely, metal industry, solar cells, biomedical applications, and optical & electrical components. Increasing technological advancement in product development and growing demand for high-quality functional films in various industries such as electronics, optics, and biomedical is expected to further propagate the magnetron sputtering systems market with a significant growth rate during the forecast period.In many industrial applications, magnetron sputtering out-performed traditional coating techniques. However, their market penetration is limited to certain niche sectors only and traditional coating technologies still capture the major share of the coating industry market. One of the main reasons for limited industry penetration is due to the high cost of sputter and other PVD coated components. As per Oerlikon Balzers Company, magnetron sputtering can add-up to the cost of tool up to 35% compared to 8% when gas nitro-carburizing treatment, it can increase the tool life up to 32 times of the uncoated tools.Electronics & optics segment to grow on account of growth in the electronics industryGrowing utilization of electronics and optical in various industries has a high demand for thin film deposition is increasing the share of electronics and optics segment in the overall magnetron sputtering systems market. Large number of sputtering application in electronics segment such as gate dielectric, printed circuit boards, sensors, surface acoustic wave (SAW) devices and spectroscopy, laser lenses, anti-glare coatings, etc. among others in optics segment is assisting the electronics and optics segment is expected to account the major share of the market during the forecast period.In addition, the magnetron sputtering systems are widely used in automobile & machinery, biomedical, and in the metal industry. In biomedical, the system is used for namely, angioplasty devices, anti-rejection coatings, radiation capsules, dental implants, etc. among others. In addition, in the automotive & machinery segment, magnetron sputtering is used for coating metals with thin film deposition to improve their efficiency.Developing the electronics industry in the Asia Pacific market is increasing proficientlyThe Asia Pacific captured the major share of the global magnetron sputtering systems market in 2019. Owing to a large number of electronics manufacturing companies, the region has a high demand for magnetron sputtering systems. In addition, the growing automobile and machinery industry of China, Japan, and India is further driving the regional market. Moreover, the presence of leading players of the market such as ULVAC, Inc. expected to further grow the market during the forecast period. In addition, a growing market of hybrid and electric vehicle, particularly in China, is expected to positively impact the market growth in future.Furthermore, North America accounted for the second-largest share of the global magnetron sputtering systems market in 2019. The well-established automotive and machinery market is the major driver of the demand in the region. Also, the presence of a large number of manufacturers such as Denton Vacuum, Angstrom Engineering Inc. and Torr International, Inc. has further impacted the growth of the regional market.List of Companies Covered: Buhler AGDenton VacuumTorr International Inc.Moorfield Nanotechnology LimitedAngstrom Engineering Inc.ULVAC, Inc.PREVAC SP. Z O.O.PVD Products, Inc.AJA INTERNATIONAL, Inc.SEMICORE Equipment, Inc. Key questions answered in this report What was the market size of magnetron sputtering systems market in 2019 and forecast up to 2028?What are the key factors driving the global magnetron sputtering systems market?What are the key market trends and high-growth opportunities observed in the magnetron sputteringsystems market?Which is the largest regional market for magnetron sputtering systems market?Which segment will grow at a faster pace? Why?Which region will drive the market growth? Why?Which players are leading the magnetron sputtering systems market?What are the key strategies adopted by the leading players operating in the market? Key Topics Covered: 1. Preface1.1. Report Description1.1.1. Purpose of the Report1.1.2. Target Audience1.1.3. USP and Key Offerings1.2. Research Scope1.3. Research Methodology1.3.1. Phase I - Secondary Research1.3.2. Phase II - Primary Research1.3.3. Phase III - Expert Panel Review1.3.4. Approach Adopted1.3.4.1. Top-Down Approach1.3.4.2. Bottom-Up Approach1.3.5. Assumptions1.4. Market Segmentation2. Executive Summary2.1. Market Snapshot: Global Magnetron Sputtering System Market (MSS) Market2.2. Global MSS Market, by Product Type, 2019 (US$ Bn)2.3. Global MSS Market, by Application, 2019 (US$ Bn)2.4. Global MSS Market, by Geography, 2019 (US$ Bn)3. Market Dynamics3.1. Introduction3.1.1. Global MSS Market Value, 2018 - 2028, (US$ Bn)3.2. Market Dynamics3.2.1. Market Drivers3.2.2. Market Restraints3.3. Attractive Investment Proposition, by Geography, 20193.4. Market Positioning of Key Players, 20193.4.1. Major Strategies Adopted by Key Players4. Global Magnetron Sputtering System (MSS) Market, by Product Type , 2018 - 2028 (US$ Bn)4.1. Overview4.2. DC Magnetron Sputtering4.3. RF Magnetron Sputtering5. Global Magnetron Sputtering System (MSS) Market, by Application, 2018 - 2028 (US$ Bn)5.1. Overview5.2. Electronics & Optics5.3. Automobile & Machinery5.4. Biomedical5.5. Others (Solar Cells, Decorative & Packaging, Architectural Glass, etc.)6. North America Magnetron Sputtering System (MSS) Market Analysis, 2018 - 2028 (US$ Bn)6.1. Overview6.1.1. North America MSS Market Value and Growth, 2018 - 2028, (US$ Bn)6.2. North America MSS Market Value, By Product Type, 2018 - 2028 (US$ Bn)6.2.1. Market Analysis6.3. North America MSS Market Value, By Application, 2018 - 2028 (US$ Bn)6.3.1. Market Analysis6.4. North America MSS Market Value, By Region/Country, 2018 - 2028 (US$ Bn)6.4.1. Market Analysis6.4.2. U.S.6.4.3. Rest of North America7. Europe Magnetron Sputtering System (MSS) Market Analysis, 2018 - 2028 (US$ Bn)7.1. Overview7.1.1. Europe MSS Market Value and Growth, 2018 - 2028, (US$ Bn)7.2. Europe MSS Market Value, By Product Type, 2018 - 2028 (US$ Bn)7.2.1. Market Analysis7.3. Europe MSS Market Value, By Application, 2018 - 2028 (US$ Bn)7.3.1. Market Analysis7.4. Europe MSS Market Value, By Region/Country, 2018 - 2028 (US$ Bn)7.4.1. Market Analysis7.4.2. U.K.7.4.3. Germany7.4.4. France7.4.5. Rest of Europe8. Asia Pacific Magnetron Sputtering System (MSS) Market Analysis, 2018 - 2028 (US$ Bn)8.1. Overview8.1.1. Asia Pacific MSS Market Value and Growth, 2018 - 2028, (US$ Bn)8.2. Asia Pacific MSS Market Value, By Product Type, 2018 - 2028 (US$ Bn)8.2.1. Market Analysis8.3. Asia Pacific MSS Market Value, By Application, 2018 - 2028 (US$ Bn)8.3.1. Market Analysis8.4. Asia Pacific MSS Market Value, By Region/Country, 2018 - 2028 (US$ Bn)8.4.1. Market Analysis8.4.2. Japan8.4.3. China8.4.4. India8.4.5. Rest of Asia Pacific9. Rest of the World Magnetron Sputtering System (MSS) Market Analysis, 2018 - 2028 (US$ Bn)9.1. Overview9.1.1. Rest of the World MSS Market Value and Growth, 2018 - 2028, (US$ Bn)9.2. Rest of the World MSS Market Value, By Product Type, 2018 - 2028 (US$ Bn)9.2.1. Market Analysis9.3. Rest of the World MSS Market Value, By Application, 2018 - 2028 (US$ Bn)9.3.1. Market Analysis9.4. Rest of the World MSS Market Value, By Region, 2018 - 2028 (US$ Bn)9.4.1. Market Analysis9.4.2. Middle East & Africa9.4.3. Latin America10. Company Profiles10.1. Buhler AG10.2. Denton Vacuum10.3. Torr International Inc.10.4. Moorfield Nanotechnology Limited10.5. Angstrom Engineering Inc.10.6. ULVAC, Inc.10.7. PREVAC SP. Z O.O.10.8. PVD Products, Inc.10.9. AJA INTERNATIONAL, Inc.10.10. SEMICORE Equipment, Inc.For more information about this report visit https://www.researchandmarkets.com/r/59ed2u CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Ireland have made their worst start to a Six Nations campaign after defeats to Wales and France.
The Global Seaweed Snacks Market size is expected to reach $3 billion by 2026, rising at a market growth of 13. 2% CAGR during the forecast period. Seaweed extracts are products used in various sectors like food, agriculture, cosmetics, and pharmaceuticals.New York, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Seaweed Snacks Market By Product, By Distribution Channel, By Region, Industry Analysis and Forecast, 2020 - 2026" - https://www.reportlinker.com/p06028134/?utm_source=GNW The application of these seaweed extracts varies in different industries. The agriculture sector uses seaweed as a component in pesticides, horticulture, and fertilizers. The food industry uses seaweed extract in the making of different snacks because of its health benefits. Seaweed extracts help in reducing the cholesterol level, improving digestion, and weight loss that makes it an important and effective part of dietary food.The rising adoption of vegan products have been witnessed over the last few years. The growing vegan population around the world is expected to propel the seaweed snacks market during the forecast period. There are many people in countries like Canada, who do not use animal products and demand healthy, clean, and natural seaweed snacks products in the market. Many people in the U.S include animal-free products in their diet to maintain healthy lifestyle. The rising vegan population is estimated to boost the demand for different sources of seaweed snack products. It is anticipated that the demand for products with new ingredients will drive the demand for the global seaweed snacks market.By ProductBased on Product, the market is segmented into Strips & Chips, Flakes, Bars and Other Products. Based on type, the strips & chips category obtained the highest market share in 2019. This category would further grow at a significant growth rate during the forecast period as the key manufacturers of the market have introduced innovative products in order to increase their product portfolio. For example, Ocean’s Halo in January 2017 launched three latest products that include chili lime, dark chocolate strip, organic sushi nori, and Korean BBQ flavored sheets.By Distribution ChannelBased on Distribution Channel, the market is segmented into Offline and Online. The online store segment is expected to record the highest CAGR over the forecast period. The attractive price offers combined with the convenience of shopping from home are propelling the sales of these products through the online platforms. Online platforms like Tesco PLC, Amazon, Sainsbury’s, Asda Stores Ltd., and Instacart are among the main online retailers around the world.By RegionBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America would exhibit a prominent CAGR during the forecast years. The rising concerns about health among the consumers along with the increasing cases of obesity have been boosting the growth of the seaweed snacks market in this region. For instance, Taokaenoi Food & Marketing PCL’s subsidiary Nora Snacks introduced a wide variety of seaweed chips in the U.S. The company also unveiled seaweed snacks on Amazon and other online stores.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include PepsiCo, Inc., CJ CheilJedang Corporation (Annie Chun’s, Inc.), Taokaenoi Food & Marketing PCL, Gimme Health Foods, Inc., KwangCheon Kim Co., Ltd. (Kimnori USA, Inc.), SeaSnax, New Frontier Foods, Inc. (Ocean’s Halo), KPOP Foods, Inc., Eden Foods, Inc., and Singha Corporation Co., Ltd. (Boon Rawd Brewery).Strategies deployed in Seaweed Snacks MarketMar-2020: Gimme Snacks introduced new Sea Salt & Avocado Oil Roasted Seaweed Snack flavor. This is the new flavor alongside its existing product line of premium USDA Organic, Non-GMO, and Gluten Free products.Sep-2018: Nora Snacks, a US subsidiary of the Thai seaweed manufacturer Taokaenoi introduced seaweed chips to America. These seaweed chips are launched through Amazon and other online retailers.Aug-2018: Singha Collaborated with Bar B Q Plaza. The collaboration was focused on introducing new Masita seaweed snack flavour, Grilled Bacon with Bar B Q Plaza Sauce combined with the unique flavour of Bar B Q Plaza’s sauce with fried seaweed.May-2018: KPOP Foods introduced one-of-a-kind organic, roasted seaweed snack called KPOP Sea Snacks with Packed with flavor and health benefits.Jan-2018: TaoKaeNoi launched Korean Style Seaweed Snack Range. This range is also available in Crispy Seaweed with Spicy Baby Clam Flavour.Nov-2017: Taokaenoi Food & Marketing agreed to acquire GIM Factory, Inc., California-incorporated organic seaweed producer. The Acquisition would expand its business in North America and Europe.Jan-2017: New Frontier Foods expanded its product lines and manufacturing capabilities by launching A first-of-its-kind Dark Chocolate Seaweed Strip, Chile Lime and Korean BBQ Flavors. These products are added to its Seaweed Snack Sheets, Organic Ocean’s Halo Sushi Nori.Scope of the StudyMarket Segments covered in the Report:By Product• Strips & Chips• Flakes• Bars• Other ProductsBy Distribution Channel• Offline• OnlineBy Geography• North Americao USo Canadao Mexicoo Rest of North America• Europeo Germanyo UKo Franceo Russiao Spaino Italyo Rest of Europe• Asia Pacifico Chinao Japano Indiao South Koreao Singaporeo Malaysiao Rest of Asia Pacific• LAMEAo Brazilo Argentinao UAEo Saudi Arabiao South Africao Nigeriao Rest of LAMEACompanies Profiled• PepsiCo, Inc.• CJ CheilJedang Corporation (Annie Chun’s, Inc.)• Taokaenoi Food & Marketing PCL• Gimme Health Foods, Inc.• KwangCheon Kim Co., Ltd. (Kimnori USA, Inc.)• SeaSnax• New Frontier Foods, Inc. (Ocean’s Halo)• KPOP Foods, Inc.• Eden Foods, Inc.• Singha Corporation Co., Ltd. (Boon Rawd Brewery)Unique Offerings • Exhaustive coverage• Highest number of market tables and figures• Subscription based model available• Guaranteed best price• Assured post sales research support with 10% customization freeRead the full report: https://www.reportlinker.com/p06028134/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001